Increased levels of glycosaminoglycans during septic shock: Relation to mortality and the antibacterial actions of plasma

Shock

Volumn 30, Issue 6, 2008, Pages 623-627

  Nelson, Axel ^a   Berkestedt, Ingrid ^a   Schmidtchen, Artur ^a   Ljunggren, Lennart ^b   Bodelsson, Mikael ^a,c  

^a LUND UNIVERSITY   (Sweden)

^b MALMÖ UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibacterial activity; Cardiac failure; Circulation; GAG; Glycocalyx; Prognosis; Sepsis; Syndecan 1

Indexed keywords

ALCIAN BLUE; GLYCOSAMINOGLYCAN; SYNDECAN 1;

ADULT; AGED; ANTIBACTERIAL ACTIVITY; ARTERIAL BLOOD; ARTICLE; BLOOD LEVEL; CELL DAMAGE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOCALYX; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; MALE; MORTALITY; PLASMA; SCORING SYSTEM; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; ESCHERICHIA COLI; FEMALE; GLYCOSAMINOGLYCANS; HUMANS; MALE; MIDDLE AGED; PLASMA; SHOCK, SEPTIC; SYNDECAN-1;

EID: 54849433850     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181777da3     Document Type: Article

References (27)

1. Aird WC: The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 101:3765-3777, 2003.
2. Parish CR: The role of heparan sulphate in inflammation. Nat Rev Immunol 6:633-643, 2006.
3. Kreuger J, Spillmann D, Li JP, Lindahl U: Interactions between heparan sulfate and proteins: the concept of specificity. J Cell Biol 174:323-327, 2006.
4. Kjellen L, Lindahl U: Proteoglycans: structures and interactions. Ann Rev Biochem 60:443-475, 1991.
5. Taylor KR, Gallo RL: Glycosaminoglycans and their proteoglycans: hostassociated molecular patterns for initiation and modulation of inflammation. FASEB J 20:9-22, 2006.
6. Baranska-Rybak W, Sonesson A, Nowicki R, Schmidtchen A: Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids. J Antimicrob Chemother 57:260-265, 2006.
7. Michel CC, Curry FE: Microvascular permeability. Physiol Rev 79:703-761, 1999.
8. van den Berg BM, Vink H, Spaan JA: The endothelial glycocalyx protects against myocardial edema. Circ Res 92:592-594, 2003.
9. Klein NJ, Sherman GI, Heyderman RS, Levin M: Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. J Cell Sci 102(Pt 4): 821-832, 1992.
10. Marechal X, Favory R, Joulin O, Montaigne D, Hassoun S, Decoster B, Zerimech F, Neviere R: Endothelial glycocalyx damage during endotoxemia coincides with microcirculatory dysfunction and vascular oxidative stress. Shock 29:572-576, 2008.
11. Mulivor AW, Lipowsky HH: Inflammation- and ischemia-induced shedding of venular glycocalyx. Am J Physiol Heart Circ Physiol 286:1672-1680, 2004.
12. Haynes A, Ruda F, Oliver J, Hamood AN, Griswold JA, Park PW, Rumbaugh KP: Syndecan 1 shedding contributes to Pseudomonas aeruginosa sepsis. Infect Immun 73:7914-7921, 2005.
13. Bashenko Y, Ilan N, Krausz MM, Vlodavsky I, Hirsh MI: Heparanase pretreatment attenuates endotoxin-induced acute lung injury in rats. Shock 28: 207-212, 2007.
14. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864-874, 1992.
15. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med 13:818-829, 1985.
16. Moreno R, Vincent JL, Matos R, Mendonca A, Cantraine F, Thijs L, Takala J, Sprung C, Antonelli M, Braining H, et al.: The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med 25:686-696, 1999.
17. Bjoernsson S: Quantitation of proteoglycans as glycosaminoglycans in biological fluids using an Alcian blue dot blot analysis. Anal Biochem 256: 229-237, 1998.
18. Lehrer RI, Rosenman M, Harwig SSSL, Jackson R, Eisenhauer P: Ultrasensitive assays for endogenous antimicrobial polypeptides. J Immunol Methods 137:167-173, 1991.
19. Scherpereel A, Depontieu F, Grigoriu B, Cavestri B, Tsicopoulos A, Gentina T, Jourdain M, Pugin J, Tonnel A-B, Lassalle P: Endocan, a new endothelial marker in human sepsis. Crit Care Med 34:532-537, 2006.
20. Oragui EE, S SN, Kyd P, Levin M: Increased excretion of urinary glycosaminoglycans in meningococcal septicemia and their relationship to proteinuria. Crit Care Med 28:3002-3008, 2000.
21. Gotte M: Syndecans in inflammation. FASEB J 17:575-591, 2003.
22. Gotte M, Joussen AM, Klein C, Andre P, Wagner DD, Hinkes MT, Kirchhof B, Adamis AP, Bernfield M: Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature. Invest Ophthalmol Vis Sci 43: 1135-1141, 2002.
23. Mulivor AW, Lipowsky HH: Role of glycocalyx in leukocyte-endothelial cell adhesion. Am J Physiol Heart Circ Physiol 283:1282-1291, 2002.
24. Rehm M, Bruegger D, Christ F, Conzen P, Thiel M, Jacob M, Chappell D, Stoeckelhuber M, Welsch U, Reichart B, et al.: Shedding of the endothelial glycocalyx in patients undergoing vascular surgery with global and regional ischemia. Circulation 116:1896-1906, 2007.
25. Nordahl EA, Rydengård V, Nyberg P, Nitsche DP, Mörgelin M, Malmsten M, Björck L, Schmidtchen A: Activation of the complement system generates antibacterial peptides. Proc Natl Acad Sci U S A 101:16879-16884, 2004.
26. Bengsch S, Boos KS, Nagel D, Seidel D, Inthorn D: Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: clinical results of a pilot study. Shock 23:494-500, 2005.
27. Staprans I, Felts JM: Isolation and characterization of glycosaminoglycans in human plasma. J Clin Invest 76:1984-1991, 1985.